[go: up one dir, main page]

BR112012001681A2 - domínios variáveis de ligação de anti-albumina sérica aperfeiçoados - Google Patents

domínios variáveis de ligação de anti-albumina sérica aperfeiçoados

Info

Publication number
BR112012001681A2
BR112012001681A2 BR112012001681A BR112012001681A BR112012001681A2 BR 112012001681 A2 BR112012001681 A2 BR 112012001681A2 BR 112012001681 A BR112012001681 A BR 112012001681A BR 112012001681 A BR112012001681 A BR 112012001681A BR 112012001681 A2 BR112012001681 A2 BR 112012001681A2
Authority
BR
Brazil
Prior art keywords
binding domains
albumin binding
serum anti
improved serum
improved
Prior art date
Application number
BR112012001681A
Other languages
English (en)
Inventor
Coulstock Edward
De Angelis Elena
Liu Haiqun
Schon Oliver
Original Assignee
Graxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graxo Group Ltd filed Critical Graxo Group Ltd
Publication of BR112012001681A2 publication Critical patent/BR112012001681A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012001681A 2009-07-16 2010-07-14 domínios variáveis de ligação de anti-albumina sérica aperfeiçoados BR112012001681A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US30755410P 2010-02-24 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
BR112012001681A2 true BR112012001681A2 (pt) 2019-09-24

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012001681A BR112012001681A2 (pt) 2009-07-16 2010-07-14 domínios variáveis de ligação de anti-albumina sérica aperfeiçoados

Country Status (15)

Country Link
US (2) US8679496B2 (pt)
EP (1) EP2454285A2 (pt)
JP (1) JP2012532620A (pt)
KR (1) KR20120038494A (pt)
CN (1) CN102574914A (pt)
AU (1) AU2010272590B2 (pt)
BR (1) BR112012001681A2 (pt)
CA (1) CA2768462A1 (pt)
EA (1) EA201270174A1 (pt)
IL (1) IL217520A0 (pt)
IN (1) IN2012DN00640A (pt)
MX (1) MX2012000765A (pt)
SG (1) SG177601A1 (pt)
WO (1) WO2011006915A2 (pt)
ZA (1) ZA201200276B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1008014A2 (pt) * 2009-02-19 2016-10-04 Glaxo Group Ltd domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
BR112012001681A2 (pt) * 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
WO2012020143A1 (en) * 2010-08-13 2012-02-16 Glaxo Group Limited Improved anti-serum albumin binding variants
US20130266567A1 (en) * 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
SI2776466T1 (sl) * 2011-11-11 2017-12-29 Ucb Biopharma Sprl Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2017041114A2 (en) * 2015-09-03 2017-03-09 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (pt) 2015-11-12 2018-06-09
HUE057241T2 (hu) * 2015-11-13 2022-04-28 Ablynx Nv Javított, szérumalbumint kötõ immunoglobulin variábilis domének
JO3740B1 (ar) 2015-11-18 2021-01-31 Merck Sharp & Dohme روابط pd1/ctla4
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CR20180278A (es) 2015-11-18 2018-08-24 Merck Sharp & Dohme Enlazadores de pd1 y/o lag3
HK1254952A1 (zh) 2015-11-18 2019-08-02 Merck Sharp & Dohme Llc Ctla4结合剂
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
KR102616835B1 (ko) * 2016-12-07 2023-12-22 아블린쓰 엔.브이. 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인
PT3571224T (pt) * 2017-01-17 2024-11-08 Ablynx Nv Ligantes de albumina sérica melhorados
IL312292A (en) * 2017-01-17 2024-06-01 Ablynx Nv Improved serum albumin binders
EP4552699A3 (en) 2017-02-16 2025-07-16 Sonnet BioTherapeutics, Inc. Albumin binding domain fusion proteins
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
MX2020003562A (es) 2017-10-10 2020-10-01 Numab Therapeutics AG Anticuerpo multiespecifico.
WO2020172528A1 (en) 2019-02-22 2020-08-27 Anwita Biosciences, Inc. Albumin binding antibodies and use thereof
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
EP4133084A1 (en) 2020-04-09 2023-02-15 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
IT202000013006A1 (it) * 2020-06-01 2021-12-01 Bioreweal S R L Processo per la produzione biologica di idrogeno e/o di metano mediante assorbimento e conversione biologica di anidride carbonica.
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN116670166A (zh) 2020-12-07 2023-08-29 Ucb生物制药有限责任公司 多特异性抗体和抗体组合
CA3208781A1 (en) 2021-02-02 2022-08-11 Bithi CHATTERJEE Multispecific antibodies having specificity for ror1 and cd3
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2002102854A2 (en) * 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
DK1737962T3 (da) 2004-03-24 2010-12-13 Domantis Ltd GAS1-universel leder
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
SG157423A1 (en) * 2004-12-02 2009-12-29 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
CN101466734A (zh) * 2005-12-01 2009-06-24 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的竞争性域抗体形式
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Egfrおよび/またはvegfに対して結合特異性を有するリガンドおよびその使用法
CN101578298A (zh) * 2006-01-24 2009-11-11 杜门蒂斯有限公司 结合il-4和/或il-13的配体
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
EP2297314B1 (en) * 2008-06-06 2015-04-15 Danisco US Inc. Compositions and methods comprising variant microbial proteases
BR112012001681A2 (pt) * 2009-07-16 2019-09-24 Graxo Group Ltd domínios variáveis de ligação de anti-albumina sérica aperfeiçoados

Also Published As

Publication number Publication date
EA201270174A1 (ru) 2012-07-30
AU2010272590A1 (en) 2012-02-02
CA2768462A1 (en) 2011-01-20
KR20120038494A (ko) 2012-04-23
JP2012532620A (ja) 2012-12-20
WO2011006915A2 (en) 2011-01-20
SG177601A1 (en) 2012-02-28
AU2010272590B2 (en) 2013-10-10
US20140140996A1 (en) 2014-05-22
MX2012000765A (es) 2012-02-13
CN102574914A (zh) 2012-07-11
IL217520A0 (en) 2012-02-29
EP2454285A2 (en) 2012-05-23
US8679496B2 (en) 2014-03-25
US20120114647A1 (en) 2012-05-10
ZA201200276B (en) 2012-09-26
IN2012DN00640A (pt) 2015-08-21
WO2011006915A3 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
BR112012001681A2 (pt) domínios variáveis de ligação de anti-albumina sérica aperfeiçoados
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BR112013014278A2 (pt) proteínas de ligação a tnf-a
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
DK2411048T3 (da) Adjuvanterende meningokok-faktor h-bindingsprotein
BRPI1013688A2 (pt) proteínas de ligação de il-17.
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
PT2406284T (pt) Anticorpos anti-bcma
BRPI0920749A2 (pt) proteínas de ligação de antagonista multialvo cd86
BRPI1007371A2 (pt) proteínas de ligação a il-1
BRPI1011005A2 (pt) anticorpos anti-epcam
EP2351777A4 (en) ANTI-MUC1 ANTIBODIES
IL234081B (en) Antibody binds cd3–epsilon in different species
IL219202A0 (en) Il-1 binding proteins
EP2337798A4 (en) SPECIFIC ANTIBODIES OF THE ASB
IL211850A0 (en) Improved antibody molecules
BRPI0918947A2 (pt) proteína de fusão de anticorpo
IL201340A (en) Antidote 3dc - epsilon in various species
EP2566517A4 (en) BINDER ANTIBODY CSF1R
EP2406399A4 (en) MIRAC PROTEINS
BRPI1013623A2 (pt) inibidores de ligação de proteína cinase
EP2262831A4 (en) ANTI-properdin antibody
FI20070853A0 (fi) Glykaania sitovat monoklonaaliset vasta-aineet
SMT201700083B (it) Anticorpi monoclonali

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.